Hi

I am delighted to share a novel discovery in our clinical trials. Our engineers have developed a method to determine if a patient has dosed their medicine, simply by analysing their voice!

The discovery has led to the announcement today of the acquisition of Life AI Corp Pty Ltd, a life sciences focused technology company that is developing predictive technologies for enhancing health and wellness. It's most progressive asset is Booze AI, due for first consumer sales launch in H2, 2025, the world's first voice activated, AI powered blood alcohol estimator on a Smartphone! More info ahead of the launch at www.booze-ai.com

Booze AI, the World's First App to Estimate Blood Alcohol Concentration over a Smartphone using Speech is currently in development and due for launch in H2, 2025. www.booze-ai.com

The speech discovery adds to a large repository of intellectual property, in the form of digital and AI related technologies the Company has developed as a protective and competitive moat around the dosing and administration of its lead candidate drug, MB22001.

This intellectual property developed is used to monitor patient’s adherence to dosage protocols, to deter misuse and immediately identify and report medication diversion to clinicians. The technology stores and analyses blood data, speech data, EEG, ECG, DNA, psychological data and biophysical information collected 24hours/7days a week from patient wearables.  It’s algorithms draw from this broad source of data to create an authoritative diagnostic and prescription tool to precision target and dose patients who are likely responders to MB22001. MindBio is now preparing to commercialize certain aspects of this technological IP through Life AI Corp and its first commercial product, Booze AI.

Booze AI, is developing the world’s first voice activated and artificial intelligence powered estimator of blood alcohol concentration over a smartphone. It’s as simple as talking to your phone and performing a few tasks to get an estimate of your blood alcohol concentration on the go. According to Google, there are an estimated 1 million searches globally for physical breathalyser units per month. Booze AI is a convenient software solution and will be available to every smartphone user. It is a potential major disruptor to this industry and the first consumer version of the product is due for launch around H2, 2025. For more information ahead of the product launch visit www.booze-ai.com

Meanwhile MindBio continues dosing in its two Phase 2B Randomized controlled trials, microdosing MB22001 in patients with cancer and patients with Major Depressive Disorder with first data and top line readouts expected late in 2025.

The commercial opportunities for MindBio’s speech discovery are significant for monitoring medication adherence including medication abuse or intoxication in patients through voice analysis and the acquisition of Life AI Corp provides an ideal platform to further develop, expand upon and commercialize MindBio’s discovery and intellectual property whilst the Company pursues drug development in clinical trials.

The acquisition of Life AI Corp is subject to closing conditions and approval from regulators.

We invite you to join us in support of creating a brighter future for mental health.

Stay Well!

JUSTIN HANKA

Chief Executive Officer & Co-Founder

MindBio Therapeutics Corp (Frankfurt: WF6), (CNSX: MBIO)

Follow CEO Justin Hanka on LinkedIn:

https://www.linkedin.com/in/justinhanka/

Follow MindBio on LinkedIn: https://www.linkedin.com/company/mindbio-therapeutics/?viewAsMember=true